ArticleHeliyon2024
Atrophy of hippocampal subfields and amygdala nuclei in subjects with mild cognitive impairment progressing to Alzheimer's disease.
Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Palmitoylethanolamide and Luteolin in Brain Aging and Cognitive Decline: Biological Rationale and Current Evidence.Nutrients · 2026Review
- Rostral associations of MRI atrophy of the amygdala and entorhinal cortex across the AD spectrum.Neuroimage. Reports · 2026Article
- Decreased Plasma IGF-1 Is Associated with Cortical Atrophy, but Not Concomitant Cerebrovascular Disease in Alzheimer's Dementia.Biomolecules · 2026Article
- A computational model to describe multi-regional brain architecture during neurodegeneration in Alzheimer's disease.Scientific reports · 2026Article
- An information-theoretic evaluation framework for CNN-LSTM-based Alzheimer's disease classification from structural MRI.Scientific reports · 2026Article
- Lamellar Normative Modelling of the Hippocampus Across the Human Lifespan.bioRxiv : the preprint server for biology · 2026Article
- Subregional limbic radiomics on FDG-PET provides accurate early detection of Alzheimer's disease.BMC medical imaging · 2026Article
- Brain Volume Alterations and Cognitive Functions in Patients with Common Variable Immunodeficiency: Evaluating the Impact of Autoimmunity.Journal of clinical medicine · 2026Article
- Impaired event-related theta spectral coherence in emotional facial expression processing in neurodegenerative disorders.Frontiers in human neuroscience · 2026Article
- Investigating Alzheimer's Disease Progression Using a Radiomics Approach: The Hippocampal-Amygdala Border in FDG-Positron Emission Tomography Scans.Neuro-degenerative diseases · 2026Article
- Validation of dementia-free status in the iranian brain imaging database using ADNI data: a transition point from middle age to older adulthood.BMC neurology · 2025Article
- Role of Cav1.3 Channels in Brain-Heart Interactions: An Unexpected Journey.Biomedicines · 2025Review
- Hippocampal subfields: volume, neuropathological vulnerability and cognitive decline in Alzheimer's and Parkinson's disease.Alzheimer's research & therapy · 2025Article
- Amygdala Nuclei Atrophy in Cognitive Impairment and Dementia: Insights from High-Resolution Magnetic Resonance Imaging.Medicina (Kaunas, Lithuania) · 2025Article
- Cocaine self-administration attenuates brain glucose metabolism and functional connectivity in rats.PloS one · 2025Article
- Medial Amygdalar Tau Is Associated With Mood Symptoms in Preclinical Alzheimer's Disease.Biological psychiatry. Cognitive neuroscience and neuroimaging · 2024Article
- Estimating individual trajectories of structural and cognitive decline in mild cognitive impairment for early prediction of progression to dementia of the Alzheimer's type.Scientific reports · 2024Article
- Medial amygdalar tau is associated with anxiety symptoms in preclinical Alzheimer's disease.bioRxiv : the preprint server for biology · 2024Article
- Humanized APP is the primary determinant of regional brain volume in humanized APOE knock-in mice: a cross-sectional ex vivo MRI study.Alzheimer's & dementia (New York, N. Y.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The hippocampus and amygdala are the first brain regions to show early signs of Alzheimer's Disease (AD) pathology. AD is preceded by a prodromal stage known as Mild Cognitive Impairment (MCI), a crucial crossroad in the clinical progression of the disease. The topographical development of AD has been the subject of extended investigation. However, it is still largely unknown how the transition from MCI to AD affects specific hippocampal and amygdala subregions. The present study is set to answer that question. We analyzed data from 223 subjects: 75 healthy controls, 52 individuals with MCI, and 96 AD patients obtained from the ADNI. The MCI group was further divided into two subgroups depending on whether individuals in the 48 months following the diagnosis either remained stable (N = 21) or progressed to AD (N = 31). A MANCOVA test evaluated group differences in the volume of distinct amygdala and hippocampal subregions obtained from magnetic resonance images. Subsequently, a stepwise linear discriminant analysis (LDA) determined which combination of magnetic resonance imaging parameters was most effective in predicting the conversion from MCI to AD. The predictive performance was assessed through a Receiver Operating Characteristic analysis. AD patients displayed widespread subregional atrophy. MCI individuals who progressed to AD showed selective atrophy of the hippocampal subiculum and tail compared to stable MCI individuals, who were undistinguishable from healthy controls. Converter MCI showed atrophy of the amygdala's accessory basal, central, and cortical nuclei. The LDA identified the hippocampal subiculum and the amygdala's lateral and accessory basal nuclei as significant predictors of MCI conversion to AD. The analysis returned a sensitivity value of 0.78 and a specificity value of 0.62. These findings highlight the importance of targeted assessments of distinct amygdala and hippocampus subregions to help dissect the clinical and pathophysiological development of the MCI to AD transition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.